Ignite Creation Date:
2025-12-24 @ 10:31 PM
Ignite Modification Date:
2026-01-25 @ 7:51 AM
Study NCT ID:
NCT00444535
Status:
COMPLETED
Last Update Posted:
2021-10-25
First Post:
2007-03-06
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Lapatinib and Bevacizumab for Metastatic Breast Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Neoplasms, Breast | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | VEGF | View |
| None | Tyrosine kinase | View |
| None | ErbB2 | View |
| None | Her2-neu | View |
| None | metastatic breast cancer | View |
| None | EGFR | View |
| None | ErbB1 | View |
| None | bevacizumab | View |
| None | lapatinib | View |
| None | breast carcinoma | View |
| None | breast cancer | View |
| None | breast lump | View |
| None | breast cancer positive for human epidermal growth factor receptor 2 … | View |
| None | HER2 positive metastatic breast cancer | View |
| None | breast cancer progression | View |
| None | estrogen-receptor (ER) positive(+) breast cancer | View |
| None | Paget's disease | View |